Bridgeway Capital Management, LLC Ardelyx, Inc. Transaction History

Bridgeway Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.68 - $4.79 $201,000 - $359,250	-75,000 Reduced 24.43%	232,000 $1.11 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $181,130 - $442,080	307,000 New	307,000 $365,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $1.17 $51,000 - $117,000	-100,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.65 - $1.18 $65,000 - $118,000	100,000 New	100,000 $107,000
Q1 2020 May 15, 2020	SELL	$4.35 - $8.79 $564,195 - $1.14 Million	-129,700 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.23 - $8.29 $571,050 - $1.12 Million	-135,000 Reduced 51.0%	129,700 $973,000
Q2 2019 Aug 14, 2019	BUY	$2.49 - $3.73 $271,659 - $406,943	109,100 Added 70.12%	264,700 $712,000
Q1 2019 May 15, 2019	SELL	$1.88 - $3.35 $47,000 - $83,750	-25,000 Reduced 13.84%	155,600 $436,000
Q4 2018 Feb 14, 2019	BUY	$1.66 - $4.16 $40,670 - $101,920	24,500 Added 15.7%	180,600 $323,000
Q3 2018 Nov 13, 2018	BUY	$3.75 - $4.65 $131,250 - $162,750	35,000 Added 28.9%	156,100 $679,000
Q4 2017 Feb 14, 2018	BUY	$4.85 - $7.8 $242,499 - $390,000	50,000 Added 70.32%	121,100 $799,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $309,285 - $405,270	71,100	71,100 $398,000

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.